Work

787P First-in-human, phase I study of CBP-1008, a first-in-class bi-specific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors

Year: 2024

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.848

Authors: N. Li, J. Gong, J. Zhang, D. Liu, Y. Chen, Y. Zhang, Y. Huang, J. Wang, J. Tang, G. Li, Y. Wang, J. Wu, S. Luo, G. Lou, W. Duan, R. Huang, M. Xu, X. Hu, L. Wu, L. Shen

Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Peking University Cancer Hospital, Fudan University Shanghai Cancer Center, Zhejiang Cancer Hospital, Qilu Hospital of Shandong University, Hubei Cancer Hospital, Hunan Cancer Hospital, Huazhong University of Science and Technology, Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Henan Cancer Hospital, Harbin Medical University, Beijing Obstetrics and Gynecology Hospital, Fudan University

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: AstraZeneca

OpenAlex ID: W4402559845

FWCI: 0.714

Cites:

Cited by: 3

Related to: 10